Company: TLSA
Filing Date: 2025-04-30
Form Type: NT 20-F
Source: 0001213900-25-037710
Chunk: 1

Company: Tiziana Life Sciences Ltd
Filing Date: 2025-04-30
Form: NT 20-F
Chunk 1
---
 filed on or before the fifth calendar day following the prescribed due date; and |
|   | -c | The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.                                                                                                                                                                                                                                                                                                                                                  |

<div align='center'>PART III

NARRATIVE</div>

State below in reasonable
detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within
the prescribed time period.

The compilation, dissemination
and review of the information required to be presented in the Form 20-F for the relevant fiscal year has imposed time constraints that
have rendered timely filing of the Form 20-F impracticable without undue hardship and expense to the registrant. The registrant undertakes
the responsibility to file such annual report no later than 15 days after its original due date.

<div align='center'>PART IV

OTHER INFORMATION</div>

(1) Name and telephone number of person to contact in regard to this
notification

| Keeren Shah |     |        -44 |     | (0)20 7495 2379   |
| (Name)      |     | -Area Code |     | -Telephone Number |

(2) Have all other periodic reports required under
Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

<div align='center'>☒ Yes ☐ No</div>

(3) Is it anticipated that any significant change
in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof?

<div align='center'>☐ Yes ☒ No</div>

If so: attach an explanation of the anticipated
change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be
made.

<div align='center'>-2-

Tiziana Life Sciences, Inc.

(Name of Registrant as Specified in Charter)</div>

Has caused this notification to be signed on its
behalf by the undersigned thereunto duly authorized.

| Dated: April